US Officials Explore AI Company Equity Stakes Ahead of OpenAI and Anthropic IPO Plans 
DeepSeek Targets $7.4 Billion Funding Round, Valuation Could Reach $59 Billion in 2026 
Foreign Firms Cash In on India's IPO Boom 
Ryan Kavanaugh and Acme AI & FX Bets on Artificial Intelligence to Reinvent Film Production Economics 
Lynas Rare Earths Names Pol Le Roux as Interim CEO Ahead of Leadership Change 
Meta Challenges Australia’s Proposed Tech Tax, Citing U.S. Trade Agreement Concerns 
SpaceX Sets IPO Price at $135 Per Share Ahead of Historic Nasdaq Debut 
CrowdStrike Beats Q1 FY2027 Expectations, Raises Outlook Despite After-Hours Stock Decline 
Sunshine Silver Raises $270 Million in U.S. IPO as 2026 Market Debut Boom Accelerates 
ASIC Launches Formal Investigation Into KPMG Australia Partners Over Client Data Misuse Allegations 
Palo Alto Networks Q3 FY2026 Earnings Surge on Strong AI Security Demand, Raises Full-Year Outlook 
TSMC Sees Strong AI-Driven Growth as Demand for Advanced Chips Continues to Surge 
Hyundai, Nvidia, and South Korea Near Deal for Major AI Technology Center 
Bayer Rules Out Monsanto Spin-Off as Roundup Lawsuits Continue to Mount 
Atlas Renewable Energy Freezes $1 Billion Brazil Investment Amid Renewable Energy Curtailment 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.
AMSBIO is a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed to the acceleration of discovery programs in medical research.
Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.”
"The unique value of our patient-specific cell models makes AMSBIO an ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand the AMSBIO cancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."
About Cellaria
Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visit www.cellariabio.com or to learn more about our cell models.
Contact: Tim Walsh for Cellaria Bio 617.512.1641 [email protected]
